ENZYME TRIGGERED MEMBRANES FOR COLONIC DRUG DELIVERY

Information

  • Research Project
  • 2545706
  • ApplicationId
    2545706
  • Core Project Number
    R44DK048191
  • Full Project Number
    5R44DK048191-03
  • Serial Number
    48191
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/15/1994 - 30 years ago
  • Project End Date
    9/29/2001 - 23 years ago
  • Program Officer Name
    PODSKALNY, JUDITH M.
  • Budget Start Date
    9/30/1997 - 27 years ago
  • Budget End Date
    9/29/2001 - 23 years ago
  • Fiscal Year
    1997
  • Support Year
    3
  • Suffix
  • Award Notice Date
    9/28/1997 - 27 years ago
Organizations

ENZYME TRIGGERED MEMBRANES FOR COLONIC DRUG DELIVERY

The objective of this program is to develop a new technology for oral delivery of drugs to the colon. The technology is based on enzyme- triggered bursting of membranes coated onto drug-containing beads. These membrane coatings contain an oil substrate for intestinal lipase. in the absence of lipase, the membranes prevent drug release, while in the presence of lipase, the membranes become permeable to water, which enters the bead and bursts the coating, releasing the drug. The combination of activation by lipase and the use of small beads should result in drug delivery that is both site-specific and time-specific - a capability that is not available with current technologies. For this Phase II program, we propose to develop a coating process to provide reproducible membrane properties, demonstrate the performance capabilities of the technology for delivering drugs with a range of properties, and determine the performance of the technology in in vivo studies in dogs. This will enable rapid commercialization of the technology for specific therapeutic applications in Phase III. The technology is expected to be useful for delivery of drugs for treatment of diseases of the colon, for systemic delivery of labile drugs, and for delivery of drugs requiring chronotherapy. PROPOSED COMMERCIAL APPLICATION: This technology would be of benefit for treatment of diseases of the colon (e.g., inflammatory bowel disease), for systemic delivery of labile drugs (e.g., peptides), for chronotherapy (e.g., hormones), for implantable drug delivery, and for sensors.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG3
  • Study Section Name
  • Organization Name
    BEND RESEARCH, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    BEND
  • Organization State
    OR
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    977018583
  • Organization District
    UNITED STATES